OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $35.83 Consensus Target Price from Analysts

OrthoPediatrics Corp. (NASDAQ:KIDS) has received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $35.83.

Several analysts have commented on the stock. Piper Sandler decreased their price objective on shares of OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $42.00 price target on shares of OrthoPediatrics in a report on Thursday, May 8th. Stifel Nicolaus dropped their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Lake Street Capital started coverage on shares of OrthoPediatrics in a report on Monday, April 7th. They set a “buy” rating and a $37.00 target price for the company. Finally, Truist Financial dropped their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a report on Friday, April 11th.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. This represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Fred Hite sold 6,443 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at $5,170,606.54. The trade was a 3.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 over the last 90 days. 32.70% of the stock is owned by insiders.

Institutional Trading of OrthoPediatrics

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in OrthoPediatrics in the fourth quarter valued at approximately $9,798,000. Point72 Asset Management L.P. purchased a new position in shares of OrthoPediatrics during the fourth quarter worth approximately $7,450,000. Wasatch Advisors LP grew its position in shares of OrthoPediatrics by 47.2% during the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock worth $16,141,000 after acquiring an additional 223,217 shares during the last quarter. Wellington Management Group LLP grew its position in shares of OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after acquiring an additional 178,078 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in OrthoPediatrics by 29.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock valued at $15,576,000 after buying an additional 152,681 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Price Performance

KIDS stock opened at $22.85 on Thursday. OrthoPediatrics has a 52 week low of $20.25 and a 52 week high of $35.99. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $22.94 and a two-hundred day simple moving average of $24.03. The firm has a market capitalization of $554.96 million, a P/E ratio of -18.58 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The firm had revenue of $52.41 million during the quarter, compared to analysts’ expectations of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. Analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.